TLDR
- INJ traded at $8.71 on Friday, extending an 11% rebound from the previous day.
- CEO Eric Chen met White House, SEC and CFTC officials on Wednesday to discuss tokenization.
- Exchange supply fell to 872,500 INJ from 1.26 million INJ, per Santiment.
- INJ broke above $8.21 resistance, with $10.09 the next level on the chart.
- CoinGecko reports INJ is up 32.3% this week.
Injective (INJ) edged higher on Friday, extending an 11% rebound from the previous day. The token traded at $8.71 at press time.
Injective CEO Eric Chen met officials from the White House, the SEC and the CFTC on Wednesday. The talks centered on tokenization and on-chain finance within US regulations.
The Injective account on X shared news of the meeting. It said the project aims to work directly with the US government and major regulators on advanced tokenization.
Injective CEO @ericinjective met with officials from the White House, SEC and CFTC in Washington yesterday. He was joined by our General Counsel, Head of Policy and Head of Research.
Injective has quietly built the foundation for tokenization to thrive in America, inside the… pic.twitter.com/Gxt2KIgBAN
— Injective 🥷 (@injective) October 15, 2026
Injective has recently secured SEC-registered transfer agent status for tokenized securities. It also has CFTC-regulated futures for the INJ token.
The project also launched the Injective mint for real-world assets, following the SEC’s innovation exemption.
Santiment data shows INJ’s social dominance at 1.1% on Friday. That means nearly 1% of crypto-related discussion is about Injective.
Chart Shows Path Toward $10
INJ trades well above its 50-day EMA at $6.94 and its 200-day EMA at $5.76. It broke the $8.21 resistance set by the October 11 low. The MACD is positive and the RSI sits near 62, which points to upward momentum without an overbought reading.
Support sits near $6.94, with deeper support at $5.76. The level to watch next is the October 13 high at $10.09, with the October 10 high at $12.44 beyond it.
Supply Leaves Exchanges as Revenue Data Draws Attention
Santiment data shows exchange supply dropped to 872,500 INJ from 1.26 million INJ.
Injective now leads all major blockchains by revenue to fully diluted market cap.
→ Ahead of Solana
→ Over 20% ahead of Arbitrum
→ Over 8x Ethereum
→ Over 10x Sui and AvalancheRevenue / FDV is one of the clearest measures of whether a network’s valuation is backed by real… pic.twitter.com/MLLzOCzqJP
— Injective 🥷 (@injective) October 15, 2026
Top non-exchange wallets held 95.46 million INJ on Thursday, up from 94.99 million on August 12.
Over the same period, the share of circulating supply in profit rose to 77.01% from 41.16%.
CoinGecko said on X that INJ is up 32.3% this week. It listed Chen’s meetings, a staking vote and Injective’s revenue figures as reasons.
Stakers are voting on IIP-709, a proposal for fixed gas fees.
An October 15 report said Injective’s revenue-to-FDV ratio is 0.95, ahead of Solana at 0.83 and Arbitrum at 0.78.
Ethereum stands at 0.11, while Sui and Avalanche are each at 0.08.
Onchain revenue flows into the INJ Community BuyBack, which removes INJ from circulation every month. Injective expects revenue to grow as it onboards new tokenization initiatives and launches products in the coming months.
